Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.76% |
| Dec 31, 2025 | -26.63% |
| Sep 30, 2025 | 94.88% |
| Jun 30, 2025 | 1,260.76% |
| Mar 31, 2025 | -92.34% |
| Dec 31, 2024 | -20.57% |
| Sep 30, 2024 | 99.69% |
| Jun 30, 2024 | 49.77% |
| Mar 31, 2024 | -70.62% |
| Dec 31, 2023 | 77.74% |
| Sep 30, 2023 | -12.98% |
| Jun 30, 2023 | 224.67% |
| Mar 31, 2023 | -186.07% |
| Dec 31, 2022 | 29.93% |
| Sep 30, 2022 | 505.33% |
| Jun 30, 2022 | -221.58% |
| Mar 31, 2022 | 290.41% |
| Dec 31, 2021 | -132.44% |
| Sep 30, 2021 | -46.81% |
| Jun 30, 2021 | 31.78% |